STAAR Surgical Company filings document the regulatory record for a NASDAQ-listed ophthalmic device company focused on phakic IOLs and the EVO family of Implantable Collamer® Lenses. Its reports and exhibits cover operating results, preliminary sales disclosures, shareholder letters, product and market commentary, and clinical or regulatory matters tied to lens-based vision correction.
Recent filings also address proxy and governance disclosure, shareholder voting matters, board and committee composition, director independence, executive appointments and separation arrangements, material agreements, capital-structure disclosure for common stock, and the termination of a previously disclosed merger agreement.
STAAR Surgical reported a strong turnaround for the quarter ended April 3, 2026. Net sales rose to $93.5 million, up 119.6% from a year earlier, driven mainly by China, where distributor sales reached $47.4 million and the EVO+ ICL launch was well received. Gross margin improved to 73.6% from 65.8% as prior cost-cutting and the Swiss manufacturing ramp began to benefit unit costs.
The company moved from a net loss of $54.2 million to net income of $5.2 million, or $0.10 per diluted share, even after $6.7 million of merger- and cooperation-related expenses and $2.7 million of restructuring charges. Operating cash flow was negative $21.7 million due to higher receivables and seasonal payments, but cash and investments remained solid at $163.9 million with working capital of $251.4 million.
Results highlight both rapid growth and concentration risk: China distributors represented 51% of net sales and 57% of trade receivables. Management expects to supply all EVO and EVO+ ICLs for China from Switzerland by the end of 2026, eliminating tariff exposure while continuing to focus on cost discipline and profitable growth.
STAAR Surgical reported a sharp turnaround in first quarter 2026. Net sales reached $93.5 million, up 119.6% from $42.6 million a year earlier, driven mainly by a recovery in China and double-digit growth in the Americas.
Gross margin improved to 73.6% from 65.8%, and the company moved from a net loss of $54.2 million to net income of $5.2 million, or $0.10 per diluted share. Adjusted EBITDA shifted from a loss of $26.3 million to a gain of $24.4 million, reflecting higher gross profit and lower operating expenses.
China net sales grew to $47.4 million, helped by strong demand for EVO+ ICL and normalized distributor inventory, while net sales excluding China were $46.1 million, up 6.0%. Cash, cash equivalents, and investments totaled $163.9 million at April 3, 2026, and the company reported no outstanding debt.
Point72 Asset Management and related filers report a 5.2% beneficial ownership stake in STAAR Surgical Company as of May 11, 2026. The filing states Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen share voting and dispositive power over 2,591,498 shares of common stock (CUSIP 852312305). The stake is held in investment funds managed by Point72; the reporting persons disclaim direct ownership.
STAAR Surgical's Interim Co-CEO and President & COO Warren Foust reported a tax-related share disposition linked to previously granted restricted stock units. On May 8, 2026, 3,448 shares of common stock were withheld at $26.69 per share to satisfy tax obligations when RSUs vested. These RSUs were part of a grant made on May 8, 2023, vesting in three equal installments of 6,777 shares on May 8 of 2024, 2025, and 2026. After this tax-withholding event, Foust directly held 66,917 shares of STAAR Surgical common stock.
STAAR Surgical’s Chief Development Officer Magda Michna reported a routine tax-related share disposition. On May 8, 2026, 1,680 shares of common stock were withheld at $26.69 per share to cover taxes on previously granted restricted stock units that vested on that date.
The RSUs were granted on May 8, 2023 and vested in three roughly equal annual installments through May 8, 2026. After the tax withholding, Michna directly owns 32,691 shares of STAAR Surgical common stock. The filing also corrects a prior typo in reported holdings, confirming the correct earlier total was 29,688 shares.
STAAR Surgical Company is asking shareholders to vote at its virtual 2026 annual meeting on June 18, 2026. The proxy seeks approval to elect seven directors, add 3.9 million shares to its Omnibus Equity Incentive Plan, ratify BDO USA as auditor, and approve executive pay on an advisory basis.
The filing details significant recent changes, including termination of an all-cash merger agreement with Alcon, a cooperation agreement with major shareholder Broadwood, board refreshment that added three investor‑aligned directors, and the appointment of interim Co‑CEOs Warren Foust and Deborah Andrews. It also outlines 2026 strategic priorities around expanding EVO lens access, improving profitability through cost and supply‑chain actions, and accelerating innovation, alongside pay‑for‑performance changes such as a 50% PSU / 50% RSU long‑term incentive mix and a redesigned bonus plan funded at 140% for 2025.
BlackRock, Inc. amended a Schedule 13G to report beneficial ownership of 6,507,911 shares of STAAR SURGICAL CO common stock, representing 13.1% of the class as of 03/31/2026.
The filing attributes 6,453,653 shares of sole voting power and lists iShares Core S&P Small-Cap ETF as a holder with more than 5% interest in the issuer’s common stock. The amendment is signed by a Managing Director on 04/24/2026.
Madison Avenue group reports beneficial ownership of 2,854,710 shares of STAAR SURGICAL common stock as of April 20, 2026. The filing states this equals approximately 5.8% of the outstanding common stock based on 49,512,749 shares outstanding as of February 27, 2026. The Schedule 13G lists Madison Avenue International LP and affiliated entities and individuals (including Eli Samaha) as reporting persons with shared voting and dispositive power over the 2,854,710 shares.
STAAR Surgical Company released preliminary results showing strong first quarter 2026 momentum. Net sales for the quarter ended April 3, 2026 are expected to exceed $90 million, up sharply from $42.6 million in the first quarter of 2025, driven mainly by growth in China and continued double-digit growth in the Americas.
The company cites a significantly improved cost structure and expects a meaningful improvement in adjusted EBITDA for the quarter. Management also notes that geopolitical and macroeconomic challenges, particularly in parts of the Middle East, EMEA and APAC, have weighed on sales there and could continue to do so. STAAR plans to report full first quarter 2026 results and file its 10-Q in early May 2026.